Effects of walking on heart rate recovery, endothelium modulators and quality of life in patients with heart failure

Eur J Cardiovasc Prev Rehabil. 2011 Aug;18(4):594-600. doi: 10.1177/1741826710397099. Epub 2011 Feb 25.

Abstract

Background: Few studies have addressed the impact of moderate unsupervised everyday physical activity in patients with chronic heart failure (CHF).

Design: We investigated the effects of a 12-week walking programme as the sole exercise intervention on heart rate recovery (HRR), index of the autonomic system equilibrium, serum modulators of endothelial function (i.e. asymmetric dimethylarginine (ADMA) and homocysteine), markers of inflammation and oxidative stress and quality of life measures (i.e. SF-36 and the Zung depression scale) in CHF patients.

Methods: Twenty-eight stabilized CHF patients of ΝYHΑ class II and III volunteered to participate either in the exercise (n = 18) or in the non-exercise (n = 10) groups. Ten age-matched healthy volunteers provided reference values. The exercise programme consisted of unsupervised 40-minute walking for five days per week.

Results: Repeated measures ANOVA revealed significant improvements in HRR (p < 0.001) in the exercise patients compared to their non-exercise counterparts. ADMA levels in CHF patients at baseline were found higher than the healthy reference volunteers (p < 0.03), while a decrease in ADMA levels after walking was associated with HRR changes (r = 0.74, p = 0.007). Homocysteine levels both at baseline and at the end of the walking intervention decreased in the exercise group, but were still higher than in the healthy individuals. Average walking distance positively correlated with homocysteine decrease (p < 0.05). Total SF-36 score significantly improved (p < 0.02) mainly due to enhancements in the physical component score (p < 0.026).

Conclusion: A 12-week unsupervised walking programme exhibits a pronounced HRR amelioration, possibly attenuates endothelial damage and induces a concomitant improvement in perceived quality of life in CHF patients.

Publication types

  • Controlled Clinical Trial

MeSH terms

  • Aged
  • Analysis of Variance
  • Arginine / analogs & derivatives
  • Arginine / blood
  • Biomarkers / blood
  • Chronic Disease
  • Endothelium, Vascular / metabolism
  • Endothelium, Vascular / physiopathology*
  • Exercise Therapy*
  • Female
  • Greece
  • Heart Failure / blood
  • Heart Failure / physiopathology
  • Heart Failure / psychology
  • Heart Failure / rehabilitation*
  • Heart Rate*
  • Homocysteine / blood
  • Humans
  • Inflammation Mediators / blood
  • Male
  • Middle Aged
  • Oxidative Stress
  • Quality of Life*
  • Recovery of Function
  • Surveys and Questionnaires
  • Time Factors
  • Treatment Outcome
  • Walking*

Substances

  • Biomarkers
  • Inflammation Mediators
  • Homocysteine
  • N,N-dimethylarginine
  • Arginine